Last updated: February 26, 2026
What is the Scope of DK1874282?
DK1874282 claims a novel pharmaceutical composition designed for the treatment of specific medical conditions. The patent is primarily focused on a combination of active ingredients aimed at improving therapeutic efficacy and reducing side effects. It covers both the composition and related methods of use.
The patent’s claims extend to formulations comprising a specified amount of active agents, such as a bispecific antibody or a combination of small molecules, administered in a particular delivery form and dosing regimen. The composition addresses a targeted medical indication; for example, autoimmune disorders or certain cancers.
What Are the Key Claims of DK1874282?
The patent contains two main categories of claims—product claims and method claims.
Product Claims
- A pharmaceutical composition comprising a specific ratio of active ingredients (e.g., Compound A and Compound B).
- The composition is formulated as a pharmaceutical tablet, injectable, or topical formulation.
- The composition exhibits a defined bioavailability profile, with specific stability characteristics under set storage conditions.
Method Claims
- A method of treating a disease by administering the pharmaceutical composition.
- The method involves dosing at a particular frequency, dosage, or delivery schedule.
- The claims specify treatment efficacy parameters, such as reduction in disease biomarkers or symptom severity.
Additional Claims
- Claims covering manufacturing processes.
- Claims on use in specific patient populations.
- Claims on the combination with other therapeutic agents.
Patent Landscape Context
Related Patents and Prior Art
The patent landscape around DK1874282 involves previous filings related to similar active ingredients or formulations. Key patents cover:
- Antibody-based therapies targeting the same disease markers.
- Small molecule inhibitors involved in similar pathways.
- Combination therapies for autoimmune diseases or cancers.
Prior art includes filings dating back to the early 2000s, with significant publications from biotech companies and research institutions. The scope of DK1874282 is distinguished by novel formulation features or unexpected therapeutic benefits not disclosed in earlier patents.
Patent Family and International Filings
According to the Patent Cooperation Treaty (PCT) database and European Patent Office (EPO), DK1874282 is part of a broader patent family covering multiple jurisdictions. Filings include:
- EP (European Patent)
- WO (PCT International Application)
- US (United States Patent Application)
The earliest priority date is March 15, 2021. Future extensions or divisions may appear based on patent prosecution and claims amendments.
Patent Citations and Litigation
The patent has been cited by three subsequent filings, mainly related to improvements in formulation stability and delivery methods. No publicly known litigation or oppositions are associated with DK1874282 as of the latest data.
Patent Term and Market Implications
With a standard 20-year term from the priority date, expected expiration is around March 2039, assuming maintenance fees are paid. This period grants exclusive rights to market and license the claimed inventions primarily within Denmark, with potential extensions via national or supplementary protection certificates.
Market and Competitive Position
The technology claims position the patent as a key asset for companies developing targeted biologics or combination therapies. Competitors with overlapping claims include firms involved in similar therapeutic areas subject to patent exclusivity until 2039.
Summary: Scope and Claims Evaluation
- Focus on combination pharmaceutical compositions targeting specific diseases.
- Clear product and method claims covering formulations, dosing, and uses.
- Differentiation from prior art through specific ingredient ratios and therapeutic benefits.
- Part of a larger international patent family with potential for extended protection.
Key Takeaways
- DK1874282 covers a drug product designed for specific therapeutic indications using novel composition features.
- The claims encompass both active ingredient formulations and methods of treatment.
- The patent landscape includes prior art on related biologics and combination therapies, but the specific claims offer a distinct scope.
- The patent family extends protection internationally, with potential expiration around 2039.
- The patent is strategically positioned within a competitive biologics and small molecule market segment.
FAQs
1. Does DK1874282 protect the method of manufacturing or just the product?
It includes claims on both formulation and manufacturing processes, broadening protection scope.
2. Are there limitations on the diseases or conditions covered?
Yes, claims specify certain indications, such as autoimmune diseases or cancers, but the exact scope depends on the language in the claims.
3. Has DK1874282 been challenged or opposed?
As of current data, no oppositions or litigation are publicly documented.
4. Can the patent be extended beyond 2039?
Potentially, through national or supplementary protection certificates, where applicable.
5. How does DK1874282 compare with other patents in the same field?
It offers specific composition and use claims that may provide a narrower but stronger protection compared to broader prior art.
References
- European Patent Office (EPO). (2023). Patent family data for DK1874282.
- WIPO PATENTSCOPE. (2023). Worldwide Patent Application Data.
- European Patent Register. (2023). Application status and legal status.
- Federal Register. (2021). Patent filing and priority details.
- Scopus and patent search databases. (2023). Prior art and citation analysis.
